Cartesian Therapeutics Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 2.9, this is below the company average, and notable indication of worsening business environment. Average receivable collection period, for the Cartesian Therapeutics Inc in Mar 31 2026 quarter, has decreased to 126 days, compared to 129 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 486 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 3204, from overall ranking in the fourth quarter 2025 at 3654.

What is Receivable Turnover Ratio?
What is Cartesian Therapeutics Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RNAC Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	-85.21 %	27.87 %	-85.05 %	-98.9 %	-12.01 %
Y / Y Revenue Change	-92.91 %	-	16.8 %	-99.11 %	-81.16 %
Receivable Turnover Ratio (TTM)	2.9	2.83	1.18	0.52	3.46
RNAC's Total Ranking	# 3204	# 3654	# 3533	# 3666	# 3275
Accounts Receivable average collection period days	126	129	311	695	105
Seq. Receivable Change	-76.59 %	54.43 %	103.95 %	-79.94 %	102.41 %
Seq. Revenue Change	-91.76 %	109.51 %	51.68 %	-72.91 %	-

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 159
Healthcare Sector	# 487
Overall Market	# 3204

Receivable Turnover Ratio Statistics
High	Average	Low
44.73	8.56	0.52
(Sep 30 2017)		(Jun 30 2025)

News about Cartesian Therapeutics Inc Receivables Turnover Ratios

Cartesian Therapeutics Begins Phase 1 Trial of Descartes-15 A Next-Generation mRNA CAR-T Therapy Achieving Br...

In a significant leap forward in the field of cancer therapy, Cartesian Therapeutics, a pioneering biotechnology firm specializing in the development of next-generation mRNA-based cell therapies, has announced that the first patient has been dosed in its first-in-human Phase 1 clinical trial evaluating Descartes-15, its novel mRNA CAR-T cell therapy. This milestone marks a crucial step in the company s mission to innovate cancer treatments that are more effective and safer for patients suffering from hematologic malignancies. Understanding CAR-T Cell Therapy Chimeric Antigen Receptor T-cell (CAR-T) therapy has transformed the landscape of oncology, providing a personalized approach that harnesses the body’s immune system to fight cancer. Traditional CAR-T therapies have already made significant impacts in treating certain blood cancers, but they are often accompanied by adverse effects and limitations in efficacy.

RNAC Company Profile • Back to RNAC Efficiency Comparisons • Compare RNAC Receivables Turnover Ratio to its Competitors

Financial Statements
Cartesian Therapeutics Inc 's Accounts Receivable	$ 0 Millions	Visit RNAC's Balance sheet
Cartesian Therapeutics Inc 's Sales TTM	$ 2 Millions	Visit RNAC's Income Statement
Sources of RNAC's Revenues		Visit RNAC's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
RNAC's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
RNAC's Growth Rates	RNAC's Roa	RNAC's Inventory Turnover Ratio	RNAC's Dividend Comparisons
RNAC's Profitability Ratios	RNAC's Roi	RNAC's Asset Turnover Ratio	RNAC's Dividend Growth
RNAC's Valuation Ratios	RNAC's Roe	RNAC's Financial Strength Ratios	RNAC's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Nutriband Inc	16.79	$ 1.803 Millions	$ 0.107 Millions
Bioadaptives Inc	16.64	$ 0.024 Millions	$ 0.001 Millions
Premier Air Charter Holdings Inc	16.33	$ 33.205 Millions	$ 2.033 Millions
Bioage Labs Inc	15.90	$ 10.316 Millions	$ 0.649 Millions
Escalon Medical Corp	15.15	$ 11.445 Millions	$ 0.756 Millions
Nurix Therapeutics Inc	15.11	$ 71.779 Millions	$ 4.750 Millions
Rosecliff Acquisition Corp I	15.05	$ 23.433 Millions	$ 1.557 Millions
Lexicon Pharmaceuticals Inc	14.91	$ 69.643 Millions	$ 4.670 Millions
Qhslab Inc	14.80	$ 2.775 Millions	$ 0.188 Millions
Nexgel Inc	14.19	$ 10.382 Millions	$ 0.732 Millions
Sutro Biopharma Inc	14.04	$ 99.608 Millions	$ 7.095 Millions
Precipio inc	13.93	$ 25.831 Millions	$ 1.854 Millions
China Pharma Holdings Inc	13.86	$ 3.992 Millions	$ 0.288 Millions
Talkspace Inc	13.67	$ 239.269 Millions	$ 17.501 Millions
Marpai Inc	13.59	$ 17.125 Millions	$ 1.261 Millions
Amneal Pharmaceuticals Inc	13.56	$ 3,045.530 Millions	$ 224.634 Millions
Corcept Therapeutics Inc	13.20	$ 769.096 Millions	$ 58.264 Millions
Xoma Royalty Corporation	13.05	$ 48.555 Millions	$ 3.720 Millions
Mannkind Corporation	13.00	$ 360.783 Millions	$ 27.757 Millions
Lifestance Health Group Inc	12.74	$ 1,494.791 Millions	$ 117.296 Millions
Chemed Corporation	12.73	$ 2,540.548 Millions	$ 199.626 Millions
Milestone Scientific Inc	12.69	$ 8.337 Millions	$ 0.657 Millions
Lftd Partners Inc	12.55	$ 36.955 Millions	$ 2.945 Millions
Clene Inc	12.47	$ 0.134 Millions	$ 0.011 Millions
Skinhealth Systems Inc	12.27	$ 295.223 Millions	$ 24.052 Millions
Cytokinetics Incorporated	12.16	$ 105.815 Millions	$ 8.702 Millions
Precision Biosciences Inc	11.94	$ 45.073 Millions	$ 3.776 Millions
Teladoc Health Inc	11.94	$ 2,514.453 Millions	$ 210.660 Millions
Option Care Health Inc	11.65	$ 5,666.577 Millions	$ 486.439 Millions
Ensysce Biosciences Inc	11.55	$ 4.708 Millions	$ 0.407 Millions

Date modified: 2026-08-30T14:56:55+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.